A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer.

Trial Profile

A Phase I, Multicenter, Open-label Study of LFA102 Administered Intravenously in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs XOMA-213 (Primary)
  • Indications Advanced breast cancer; Prostate cancer; Uterine leiomyoma
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 29 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 24 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top